Cart
sales@molnova.com
Dihydrobonducellin
CAS No. 103680-87-1
Dihydrobonducellin( —— )
Catalog No. M31342 CAS No. 103680-87-1
Dihydrobonducellin has immunopharmacological activity, it significantly inhibits the production of IL-2 and IFN-gamma in activated PBMC in a concentration-dependent manner.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 565 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDihydrobonducellin
-
NoteResearch use only, not for human use.
-
Brief DescriptionDihydrobonducellin has immunopharmacological activity, it significantly inhibits the production of IL-2 and IFN-gamma in activated PBMC in a concentration-dependent manner.
-
DescriptionDihydrobonducellin has immunopharmacological activity, it significantly inhibits the production of IL-2 and IFN-gamma in activated PBMC in a concentration-dependent manner.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number103680-87-1
-
Formula Weight284.3
-
Molecular FormulaC17H16O4
-
Purity>98% (HPLC)
-
SolubilityDMSO, Pyridine, Methanol, Ethanol, etc.
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
4-O-Cinnamoylquinic ...
4-O-Cinnamoylquinic acid is a natural product for research related to life sciences.
-
Siplizumab
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.
-
Przewaquinone A
Przewaquinone A has antitumor activity.
